The Technical Analyst
Aligos Therapeutics, Inc. [ALGS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aligos Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.43% $0.750
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 54.43 mill |
| EPS: | -1.360 |
| P/E: | -0.550 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 72.58 mill |
| Avg Daily Volume: | 0.384 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.550 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.550 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.528 (-29.59%) $-0.222 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.662 - 0.838 ( +/- 11.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Mcclure Matthew W. | Buy | 72 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Calhoun Lesley Ann | Buy | 308 940 | Stock Option (Right to Buy) |
| 2024-03-01 | Symons Julian A. | Buy | 72 000 | Stock Option (Right to Buy) |
| 2024-03-01 | Blatt Lawrence | Buy | 965 435 | Stock Option (Right to Buy) |
| 2024-02-28 | Hirth Peter | Buy | 4 411 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 82.24 |
| Last 96 transactions |
| Buy: 18 924 669 | Sell: 1 675 487 |
Forecast:
16:00 - $0.750
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.750
Forecast 2: 16:00 - $0.750
Forecast 3: 16:00 - $0.750
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.750 (-5.43% ) |
| Volume | 0.139 mill |
| Avg. Vol. | 0.384 mill |
| % of Avg. Vol | 36.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALGS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-27 08:00:00 - Press Release
Aligos Therapeutics Presents Positive Clinical Data At Apasl 2024 From Alg-055009 And Alg-000184 Phase 1 Studies
South san francisco, calif., march 27, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd annual meeting of the asian pacific association for the study of the liver (apasl) 2024, being held march 27-31, 2024 in kyoto, japan.
2024-03-12 16:05:00 - Press Release
Aligos Therapeutics Reports Recent Business Progress And fourth Quarter And Full Year 2023 Financial Results
South san francisco, calif., march 12, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.
2024-03-05 16:05:00 - Press Release
Aligos Therapeutics To Announce 4th Quarter 2023 Financial Results On March 12, 2024
South san francisco, calif., march 05, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the company's fourth quarter 2023 financial results on tuesday, march 12, 2024, after the close of the u.s. financial markets.
2024-02-26 08:00:00 - Press Release
Aligos Therapeutics To Participate In The Leerink Partners Global Biopharma Conference 2024
South san francisco, calif., feb. 26, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the leerink partners global biopharma conference 2024 being held in miami, florida on march 11-13, 2024.
2024-02-20 08:00:00 - Press Release
Aligos Therapeutics To Host Kol Event To Discuss Phase 2a Herald Study Of Alg-055009 In Mash On March 7, 2024
South san francisco, calif., feb. 20, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual key opinion leader (kol) event featuring stephen harrison, md, visiting professor in the radcliffe department of medicine at the university of oxford, uk, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (mash, previously known as nash) and aligos' phase 2a herald study, intended to evaluate the safety and efficacy of alg-055009, on thursday, march 7, 2024 at 4:00 pm et.
Latest News
2024-03-27 10:56:03 - Zacks Investment Research
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
2024-03-05 16:05:00 - GlobeNewsWire
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's fourth quarter 2023 financial results on Tuesday, March 12, 2024, after the close of the U.S. financial markets.
2024-01-05 11:18:48 - Zacks Investment Research
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
2023-11-20 16:05:00 - GlobeNewsWire
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.
2023-11-20 09:10:38 - InvestorPlace
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?
Aligos Therapeutics (NASDAQ:ALGS) stock is falling on Monday after the clinical-stage biopharmaceutical company announced plans for a porposed public share offering. According to a filing with the Securities and Exchange Commission (SEC), the selling stockholders are preparing to offer as many as 168,725,925 shares of ALGS stock.
2023-06-07 07:30:00 - GlobeNewsWire
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
2023-05-24 17:26:00 - GlobeNewsWire
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.
2023-05-04 20:30:12 - Zacks Investment Research
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.84 per share a year ago.
2023-04-27 16:05:00 - GlobeNewsWire
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will report the Company's first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.
2023-04-11 18:50:00 - GlobeNewsWire
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. The presentations will be available on the Scientific Presentations and Conferences page on Aligos' corporate website following the meeting.